Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700945 · ClinicalTrials.gov registry record · NA
Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin
A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- NA
- Development phase
- 496
- Enrollment target
NCT02700945 is a NA study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 496 participants.
The verdict
NCT02700945, a NA study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- NA
- Development phase
- 496 participants
- Enrollment target
Study Summary
The purpose of the Stroke AF study is to compare the incidence of atrial fibrillation (AF) through 12 months between continuous cardiac rhythm monitoring with the Reveal LINQ™ Insertable Cardiac Monitor (ICM) (continuous monitoring arm) and standard of care (SoC) medical treatment (control arm) in subjects with a recent ischemic stroke of presumed known origin.
Interventions
- DEVICE Reveal LINQ™ Insertable Cardiac Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2016-03 |
| Est. Completion | 2022-07-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02700945
The ClinicalTrials.gov registry entry for NCT02700945 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reveal LINQ™ Insertable Cardiac Monitor is the first listed.
NCT02700945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02700945 about?
NCT02700945 is a clinical study titled "Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin". The purpose of the Stroke AF study is to compare the incidence of atrial fibrillation (AF) through 12 months between continuous cardiac rhythm monitoring with the Reveal LINQ™ Insertable Cardiac Monitor (ICM) (continuous monitoring arm) and standard of care (SoC) medical treatment (control arm) in s...
What is the current status of trial NCT02700945?
This trial is currently completed. It is a NA study. The enrollment target is 496 participants. The study started on 2016-03. Estimated completion is 2022-07-28.
What interventions are being tested in trial NCT02700945?
The interventions under investigation include: Reveal LINQ™ Insertable Cardiac Monitor (DEVICE).
Who is sponsoring clinical trial NCT02700945?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.